$Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study$

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study

Objectives: To determine efficacy and safety of sacubitril/valsartan compared with enalapril in Indian patients of PARADIGM-HF trial. Methods: A randomized, double-blind, active-controlled, phase III sub-study (NCT01035255) was conducted between April 2010 and May 2014. Patients with chronic heart f...

Full description

Bibliographic Details
Main Authors:	Anil Ranjeetmal Jain, Rakesh Kumar Aggarwal, Nanyam Srinivas Rao, Gauri Billa, Shankar Kumar
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Indian Heart Journal
Subjects:	All-cause mortality Cardiovascular death HF hospitalization Indian
Online Access:	http://www.sciencedirect.com/science/article/pii/S001948322030239X

Similar Items

Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Sameer Bhaskar GOKHALE, et al.
Published: (2021-07-01)

Angioedema with concomitant use of sacubitril/valsartan and enalapril
by: Logamoorthy Ramamoorthy, et al.
Published: (2023-01-01)

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
by: Ying Zhao, et al.
Published: (2022-07-01)

Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review
by: Aziz Rezapour, et al.
Published: (2022-10-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
by: Zakiyah N, et al.
Published: (2021-10-01)

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
by: Sokos GG, et al.
Published: (2020-01-01)

Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum
by: Xiaojing Chen, et al.
Published: (2023-12-01)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
by: Yue Wu, et al.
Published: (2020-07-01)

Cost-consequence analysis (CCA) of sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEi) in chronic heart failure patients with reduced ejection fraction (HFrEF) in Indian healthcare setting
by: Sameee Bhasker Gokale, et al.
Published: (2020-11-01)

Sacubitril/valsartan: from the PARADIGM-HF trial results to heart failure patients in internal medicine. A narrative review
by: Valerio Verdiani
Published: (2021-03-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023-03-01)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
by: Tahir Saleem Bhat, et al.
Published: (2022-05-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction
by: Martin Negreira-Caamaño, et al.
Published: (2023-02-01)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023-01-01)

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
by: Zanfina Ademi, et al.
Published: (2017-11-01)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
by: Swathi Pathadka, et al.
Published: (2021-01-01)

Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF
by: Henan Liu, et al.
Published: (2024-04-01)

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
by: Yevgeniy Khariton, et al.
Published: (2021-02-01)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021-04-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
by: Matteo Landolfo, et al.
Published: (2020-12-01)

Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01)

Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction
by: Eunice Yang, et al.
Published: (2022-10-01)

Non‐severe aortic regurgitation increases short‐term mortality in acute heart failure with preserved ejection fraction
by: Tamila Abdurashidova, et al.
Published: (2020-12-01)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
by: Chien-Yi Hsu, et al.
Published: (2022-07-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
by: Francesco Giallauria, et al.
Published: (2020-06-01)